Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG001 Injection in Paroxysmal Nocturnal Hemoglobinuria (Phase II, China)
ChiCTR2600126558Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CG001 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion of participants with sustained Hb increase ≥20 g/L without RBC transfusion at Week 24. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CG001
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on ChiCTR2600126558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126558.